Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes
Jeffrey J. Wallin(Unknown), Lori S. Friedman, Kyla M. Grimshaw(Horizon Discovery (United Kingdom)), Jeffrey Eastham‐Anderson, Sabrina Arena(Candiolo Cancer Institute), Marcia Belvin(CytomX Therapeutics (United States)), Kyle A. Edgar, Ross S. Francis, Peter M. Haverty, Alberto Bardelli(IFOM), Sue Griffin, Jane Guan, Wei Zhou(Broad Institute), Klaus P. Hoeflich(Pivot), C Torrance(Horizon Discovery (United Kingdom)), Anthony C. Torres
Cited by 49
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770